DFTXDefinium Therapeutics, Inc.

HealthcareUSD
$43.79

The financials

Definium Therapeutics, Inc. by the numbers

Definium Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$75M−$41Mn/a
Net income−$159M−$43Mn/a
Diluted EPS−$1.44−$0.50n/a

Biotechnology

Ranks #8 of 145 by Smart Score

Compare peers
LGND+3.9%
Ligand Pharmaceuticals Incorporated
BLTE-0.62%
Belite Bio, Inc
CGON+6.0%
CG Oncology, Inc.
LEGN-3.2%
Legend Biotech Corporation
TVTX+2.3%
Travere Therapeutics, Inc.
XENE+2.2%
Xenon Pharmaceuticals Inc.